Latest News

Seroba Kernel and venBio co-lead $20m Investment in Heart Metabolics

Company Established in Ireland as Part of the Financing. DUBLIN – April 17, 2014 – Heart Metabolics Limited, a new Irish biotechnology company focused on the development of drugs for cardio-metabolic diseases, has announced the completion of a $20 million Series A financing co-led by venBio (USA), and Seroba Kernel Life Sciences (Ireland), with additional...


Venture capital firms with €6 billion in funds target Irish medtech sector.

Dublin, Ireland, March 28, 2014.  Over 30 venture capital firms with more than €6 billion in funds under management are meeting in Dublin on April 8 for three days to explore opportunities to invest in the burgeoning Irish medical technology sector. Leading international names such as Omnes Capital, Abingworth and Sofinnova will be among the big players eyeing the sector...


New Screening Tool for Osteoporosis.

10 March 2014   Seroba Kernel’s investee company, Crescent Diagnostics Ltd (“Crescent”), has launched Osentia™, a new convenient screening test which identifies those at risk of fragility fracture by analysing finger or toe nail clippings. Launching in the UK, Osentia™ is available online and will shortly be available direct from pharmacies. The test enables...


< back to home page